Initial steroid bolus injection promotes vigorous CD8+ alloreactive responses toward early graft acceptance immediately after liver transplantation in humans

Liver Transplantation

Volumn 13, Issue 9, 2007, Pages 1262-1271

  Egawa, Hiroto ^a   Uemoto, Shingi ^a   Takada, Yasutugu ^a   Ozawa, Kazue ^b   Teramukai, Satoshi ^c   Haga, Hironori ^c   Kasahara, Mureo ^a   Ogawa, Kouhei ^a   Sato, Hiroshi ^d   Ono, Masako ^b   Takai, Kenji ^e   Fukushima, Masanori ^c   Inaba, Kayo ^a   Tanaka, Kolchi ^f  

^a KYOTO UNIVERSITY   (Japan)

^b Hepatic Disease Research Institute   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e SRL INC   (Japan)

^f INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12 RECEPTOR BETA1; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERFORIN; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOIMMUNITY; ARTICLE; BOLUS INJECTION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GRAFT PERFUSION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; UPREGULATION;

ADRENAL CORTEX HORMONES; BLOOD LOSS, SURGICAL; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34648825196     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21232     Document Type: Article

References (44)

1. Gane EJ, Portmann BC, Naoumov NV, Smith RM, Vnderhill JA, Donaldson PT, et al. Long-term outcome of heapitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
2. Magy N, Cribier B, Schmitt C, Ellero B, Jaeck D, Boudjema K, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999;21:253-261.
3. McHutchison JG, Ponnudurai R, Bylund DL, Angulano A, Pockros PJ, Mondala T, Wilkes LB. Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial. J Clin Gastroenterol 2001;32:133-137.
4. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32: 1125-1130.
5. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256.
6. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow up. Transplantation 2004;77:226-231.
7. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;1:167-177.
8. Pirenne J, Aerts R, Koshiba T, Van Gelder F, Roskams T, Schetz M, et al. Steroid-free immunosuppression during and after liver transplantation-a 3-yr follow-up report. Clin Transplant 2003;17:177-182.
9. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111:1887-1895.
10. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002;2: 417-426.
11. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-224.
12. Tanaka K, Ozawa K, Teramukai S, Takada Y, Egawa H, Kaihara S, et al. Classification of human liver transplant recipients by their preoperative CD8+ T cell subpopulation and its relation to outcome. Liver Transpl 2006;12: 792-800.
13. Timm JA, Thoman ML. Maturation of CD4+ lymphocytes in the aged microenvironment results in a memory-enriched population. J Immunol 1999;162:711-717.
14. Martinez OM, Rosen HR. Basic concepts in transplant immunology. Liver Transpl 2005;11:370-381.
15. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med 2002; 8:220-222.
16. Demetris AJ, Qian S, Sun H, Fung JJ, Yagihashi A, Murase N, et al. Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol 1991;138:609-618.
17. Illigens BM, Yamada A, Fedoseyeva EV, Anosova N, Boisgerault F, Valujskikh A, et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 2002;63:912-925.
18. Trinchieri G. Interleukin-12 and the regulation of innate resistanceandadaptiveimmunity. NatRevImmunol2003;3: 133-146.
19. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp 130. J Immunol 1994;153:128-136.
20. Presky DH, Gubler U, Chizzonite RA, Gately MK. IL12 receptors and receptor antagonists. Res Immunol 1995; 146:439-445.
21. Presky DH, Yang H, Minetti W, Chua AO, Nabavi N, Wu CY, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996;93:14002-14007.
22. Piccotti JR, Li K, Chan SY, Eichwald EJ, Bishop DK. Interleukin-12 (IL-12)-driven alloimmune responses in vitro and in vivo: requirement for beta1 subunit of the IL-12 receptor. Transplantation 1999;67:1453-1460.
23. Bofill M, Almirall E, McQuaid A, Pena R, Ruiz-Hernandez R, Naranjo M, et al. Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood. Clin Exp Immunol 2004;138:460-465.
24. Tanaka K, Inomata Y, Kaihara S. Living-donor liver transplantation. Surgical techniques and innovation. Barcelona, Spain: Prous Science, 2003. pp. 65-95.
25. Banff Working Group; Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501.
26. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry. J Clin Invest 1997;99:1739-1750.
27. Everitt BS, Landau S, Leese M. Hierarchical clustering. In: Everitt BS, Landau S, Leese M, eds. Cluster analysis, 4th ed. London: Arnold, 2001:55-89.
28. Yu AS, Ahmed A, Keefe EB. Liver transplantation: evolving patient selection criteria. Can J Gastroenterol 2001; 15:729-738.
29. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-385.
30. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999;162:3256-3262.
31. Gish RG, Krams SM, Martinez OM. Interleukin-12: a possible cytotoxic T-lymphocyte differentiation factor in allograft recipients. Transplant Proc 1995;27:459-460.
32. Li L, Sad S, Kagi D, Mosmann TR. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 1997; 158:4152-4161.
33. Matesic D, Valujskikh A, Pearlman E, Higgins AW, Gillian AC, Heeger PS. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. J Immunol 1998;161:5236-5244.
34. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
35. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 1998;10:1593-1598.
36. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med 2001:49:442-449.
37. + T cells toward Th2 responses. J Leukoc Biol 2000;68:633-640.
38. Woltman AM, de Fijter JM, Kamerling SW, Paul LC, Daha MR, van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 2000;30:1807-1812.
39. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cell, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353: 2654-2666.
40. Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, Mandoki JJ, Lopez-Gonzalez JS. Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 2005;47:361-371.
41. Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006;177:6962-6973.
42. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003;9:S58-62.
43. Taylor DK, Neujahr D, Turka LA. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 2004;16:558-564.
44. Washbutn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72:1675-1679.